Scarica l'app Stockscreener
2.15
0.92%
-0.02
Dopo l'orario di chiusura:
2.09
-0.06
-2.79%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.17
Aprire:
$2.18
Volume 24 ore:
59,111
Relative Volume:
0.88
Capitalizzazione di mercato:
$91.10M
Reddito:
$2.70M
Utile/perdita netta:
$5.53M
Rapporto P/E:
19.55
EPS:
0.11
Flusso di cassa netto:
$-10.55M
1 W Prestazione:
+0.94%
1M Prestazione:
+0.47%
6M Prestazione:
-9.28%
1 anno Prestazione:
-19.78%
Intervallo 1D:
$2.1001
$2.18
Intervallo di 1 settimana:
$2.06
$2.25
Portata 52W:
$1.82
$3.09
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Nome
Oramed Pharmaceuticals Inc
Settore
Industria
Telefono
646-844-1164
Indirizzo
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Confronta ORMP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.15 | 91.10M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-09 | Iniziato | National Securities | Buy |
| 2020-12-03 | Iniziato | Alliance Global Partners | Buy |
| 2020-03-11 | Iniziato | Aegis Capital | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-12-11 | Ripresa | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Reiterato | FBR Capital | Outperform |
| 2015-12-01 | Reiterato | H.C. Wainwright | Buy |
| 2015-11-19 | Iniziato | FBR Capital | Outperform |
| 2015-04-13 | Ripresa | MLV & Co | Buy |
| 2014-01-30 | Reiterato | Aegis Capital | Buy |
| 2014-01-08 | Reiterato | Aegis Capital | Buy |
| 2014-01-08 | Iniziato | MLV & Co | Buy |
| 2013-12-03 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Oramed Pharmaceuticals Inc Borsa (ORMP) Ultime notizie
Oramed Pharmaceuticals : Announces Xiaoming Gao Joins Board of Directors - marketscreener.com
Oral Biologics Market Outlook 2025: Rising Demand, Market Size, - openPR.com
Two Sigma Advisers LP Invests $662,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Type 2 Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com
Oral Biologics Market in 2025-2032 Detailed Study Analysis with - openPR.com
Acusphere (OTCMKTS:ACUS) versus Oramed Pharmaceuticals (NASDAQ:ORMP) Critical Comparison - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below 200-Day Moving Average – Should You Sell? - Defense World
Oramed Pharm Extends Stock Buyback Program - TipRanks
Dimensional Fund Advisors LP Grows Stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World
The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable - Yahoo Finance
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com - Defense World
Oramed: Q1 Earnings Snapshot - New Haven Register
Alpha Tau Medical appoints new board member By Investing.com - Investing.com India
Alpha Tau Medical appoints new board member - Investing.com
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors - GlobeNewswire
StockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to Sell - Defense World
Renaissance Technologies LLC Trims Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World
LPL Financial LLC Sells 21,250 Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World
Oramed Invests $36.9 Million In Alpha Tau For Strategic Growth - Finimize
Alpha Tau Medical (DRTS) Secures $36.9M in Direct Offering with Oramed Pharmaceuticals | DRTS Stock News - GuruFocus
Oramed invests $36.9 million in Alpha Tau cancer therapy By Investing.com - Investing.com
Alpha Tau Closes $36.9 Mln Offering And Forms Strategic Alliance With Oramed Pharmaceuticals - Nasdaq
Oramed Pharmaceuticals Announces $36.9 Million Investment And Strategic Collaboration With Alpha Tau Medical - marketscreener.com
Alpha Tau Announces Closing of $36.9 Million Registered - GlobeNewswire
Major Biotech Deal: Alpha Tau Medical Secures $36.9M Investment to Accelerate Cancer Treatment Innovation - Stock Titan
Oramed Closes $36.9M Strategic Investment in Alpha Tau Medical - citybiz
Oramed Completes $36.9 Million Strategic Investment in Alpha Tau Medical - MarketScreener
Press Release Distribution & PR Platform - ACCESS Newswire
ORMPOramed Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
What To Expect From Tesla’s (TSLA) Q1 Earnings - The Globe and Mail
Oramed stock hits 52-week low at $1.95 amid market challenges - Investing.com Australia
Oramed stock hits 52-week low at $1.95 amid market challenges By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals Inc. (ORMP) reports earnings - Quartz
Oral Biologics Market Is Booming Worldwide 2025-2032 | Biocon - openPR.com
Oramed Pharmaceuticals Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Simply Wall St
Oramed Pharmaceuticals Stock Plummets After Insulin Test Results - The Wall Street Journal
Tianhui Biotech and Oramed Pharmaceuticals’ Investment in OraTech Pharmaceuticals - Global Legal Chronicle
AllPennyStocks.com Releases a Special Report on Oramed Pharmaceuticals Inc. - ACCESS Newswire
Oramed advances oral insulin, plans Phase 3 trial and dividend - Investing.com
Oramed advances oral insulin, plans Phase 3 trial and dividend By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals Issues Letter to Shareholders - PR Newswire
ORMP stock touches 52-week low at $2 amid market challenges By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals Inc Azioni (ORMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
1.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):